作者
Georgios Schoretsanitis, Pierre Baumann, Andreas Conca, Otto Dietmaier, Giancarlo Giupponi, Gerhard Gründer, Martina Hahn, Xenia Hart, Ursula Havemann-Reinecke, Gudrun Hefner, Maxim Kuzin, Rainald Mössner, Daria Piacentino, Werner Steimer, Gerald Zernig, Christoph Hiemke
发表日期
2021/2/1
来源
Therapeutic drug monitoring
卷号
43
期号
1
页码范围
79-102
出版商
LWW
简介
Background:
The use of therapeutic drug monitoring (TDM) to guide treatment with long-acting injectable (LAI) antipsychotics, which are increasingly prescribed, remains a matter of debate. The aim of this review was to provide a practical framework for the integration of TDM when switching from an oral formulation to the LAI counterpart, and in maintenance treatment.
Methods:
The authors critically reviewed 3 types of data:(1) positron emission tomography data evaluating dopamine (D2/D3) receptor occupancy related to antipsychotic concentrations in serum or plasma; D2/D3 receptors are embraced as target sites in the brain for antipsychotic efficacy and tolerability,(2) pharmacokinetic studies evaluating the switch from oral to LAI antipsychotics, and (3) pharmacokinetic data for LAI formulations. Based on these data, indications for TDM and therapeutic reference ranges were considered for LAI antipsychotics …
学术搜索中的文章
G Schoretsanitis, P Baumann, A Conca, O Dietmaier… - Therapeutic drug monitoring, 2021